Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 215

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets

Open access
Chen, Bin, Ma, Li, Paik, Hyojung, Sirota, Marina, Wei, Wei, Chua, Mei-Sze, So, Samuel, Butte, Atul J. · 2017 · Nature Communications

Abstract

The decreasing cost of genomic technologies has enabled the molecular characterization of large-scale clinical disease samples and of molecular changes upon drug treatment in various disease models. Exploring methods to relate diseases to potentially efficacious drugs through various molecular features is critically important in the discovery of new therapeutics. Here we show that the potency of a drug to reverse cancer-associated gene expression changes positively correlates with that drug’s efficacy in preclinical models of breast, liver and colon cancers. Using a systems-based approach, we predict four compounds showing high potency to reverse gene expression in liver cancer and validate that all four compounds are effective in five liver cancer cell lines. The in vivo efficacy of pyrvinium pamoate is further confirmed in a subcutaneous xenograft model. In conclusion, this systems-based approach may be complementary to the traditional target-based approach in connecting diseases to potentially efficacious drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms16022

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 50

  1. Hoadley, K. A. et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158, 929–944 (2014). · DOI · Paper page
  2. Hakimi, A. A. et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell 29, 104–116 (2016). · DOI · Paper page
  3. Zhang, H. et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell 166, 755–765 (2016). · DOI · Paper page
  4. Chen, B. & Butte, A. J. Leveraging big data to transform target selection and drug discovery. Clin. Pharmacol. Ther. 99, 285–297 (2015). · DOI · Paper page
  5. Wilmes, A. et al. Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. J. Proteomics 79, 180–194 (2013). · DOI · Paper page
  6. Abelin, J. G. et al. Reduced-representation phosphosignatures measured by quantitative targeted MS capture cellular states and enable large-scale comparison of drug-induced phenotypes. Mol. Cell. Proteomics 15, 1622–1641 (2016). · DOI
  7. Lamb, J. et al. The connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929–1935 (2006). · DOI · Paper page
  8. Jahchan, N. S. et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov. 3, 1364–1377 (2013). · DOI · Paper page
  9. van Noort, V. et al. Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-expression profiling. Cancer Res. 74, 5690–5699 (2014). · DOI
  10. Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77 (2011). · DOI · Paper page
  11. Pessetto, Z. Y. et al. In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma. Oncotarget 8, 4079–4095 (2016). · DOI
  12. Zerbini, L. F. et al. Computational repositioning and preclinical validation of pentamidine for renal cell cancer. Molecular cancer therapeutics 13, 1929–1941 (2014). · DOI
  13. Dudley, J. T. et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci. Transl. Med. 3, 96ra76 (2011). · DOI · Paper page
  14. Brum, A. M. et al. Connectivity map-based discovery of parbendazole reveals targetable human osteogenic pathway. Proc. Natl Acad. Sci. USA 112, 12711–12716 (2015). · DOI
  15. Cheng, J., Yang, L., Kumar, V. & Agarwal, P. Systematic evaluation of connectivity map for disease indications. Genome Med. 6, 540 (2014). · DOI
  16. Wagner, A. et al. Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia. Mol. Syst. Biol. 11, 791 (2015). · DOI
  17. Fallahi-Sichani, M., Honarnejad, S., Heiser, L. M., Gray, J. W. & Sorger, P. K. Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat. Chem.l Biol. 9, 708–714 (2013). · DOI · Paper page
  18. Demontis, G. C., Ratto, G. M., Bisti, S. & Cervetto, L. Effect of blocking the Na+/K+ ATPase on Ca2+ extrusion and light adaptation in mammalian retinal rods. Biophys. J. 69, 439–450 (1995). · DOI
  19. Park, K. S. et al. FCCP depolarizes plasma membrane potential by activating proton and Na+ currents in bovine aortic endothelial cells. Pflugers Arch.y 443, 344–352 (2002). · DOI
  20. Alao, J. P. & Sunnerhagen, P. The ATM and ATR inhibitors CGK733 and caffeine suppress cyclin D1 levels and inhibit cell proliferation. Radiat. Oncol. 4, 51 (2009). · DOI
  21. Xu, W. et al. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer. PLoS ONE 8, e71508 (2013). · DOI
  22. Pez, F. et al. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J. Hepatol. 59, 1107–1117 (2013). · DOI · Paper page
  23. Lorente-Trigos, A., Varnat, F., Melotti, A. & Ruiz i Altaba, A. BMP signaling promotes the growth of primary human colon carcinomas in vivo. J. Mol. Cell Biol. 2, 318–332 (2010). · DOI
  24. Li, Y. et al. G protein-coupled estrogen receptor is involved in modulating colonic motor function via nitric oxide release in C57BL/6 female mice. Neurogastroenterol. Motil. 28, 432–442 (2016). · DOI
  25. Lyu, J. H. et al. RGS2 suppresses breast cancer cell growth via a MCPIP1-dependent pathway. J. Cell. Biochem. 116, 260–267 (2015). · DOI
  26. Hao, M. W. et al. Transcription factor EGR-1 inhibits growth of hepatocellular carcinoma and esophageal carcinoma cell lines. World J. Gastroenterol. 8, 203–207 (2002). · DOI
  27. Tice, D. A., Soloviev, I. & Polakis, P. Activation of the Wnt pathway interferes with serum response element-driven transcription of immediate early genes. J. Biol. Chem. 277, 6118–6123 (2002). · DOI
  28. Huang, M., Shen, A., Ding, J. & Geng, M. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol. Sci. 35, 41–50 (2014). · DOI · Paper page
  29. Neal, J. W. & Sledge, G. W. Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours. Nat. Rev. 11, 627–628 (2014).
  30. Hoelder, S., Clarke, P. A. & Workman, P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol. Oncol. 6, 155–176 (2012). · DOI · Paper page
  31. Kidd, B. A. et al. Mapping the effects of drugs on the immune system. Nat. Biotechnol. 34, 47–54 (2016). · DOI
  32. Iorio, F. et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl Acad. Sci. USA 107, 14621–14626 (2010). · DOI · Paper page
  33. Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740–754 (2016). · DOI · Paper page
  34. Yu, D. H. et al. Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy. PLoS ONE 3, e3951 (2008). · DOI
  35. Venugopal, C. et al. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells. Clin. Cancer Res. 21, 5324–5337 (2015). · DOI
  36. Deng, L. et al. Pyrvinium targets autophagy addiction to promote cancer cell death. Cell Death Dis. 4, e614 (2013). · DOI
  37. Hernandez-Vargas, H., Palacios, J. & Moreno-Bueno, G. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene 26, 2902–2913 (2007). · DOI
  38. Niepel, M. et al. Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines. Sci. Signal. 6, ra84 (2013). · DOI
  39. Wei, S. et al. Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol. Oncol. 7, 297–307 (2013). · DOI
  40. Chen, B., Sirota, M., Fan-Minogue, H., Hadley, D. & Butte, A. J. Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research. BMC Med. Genomics 8, (Suppl 2): S5 (2015). · DOI
  41. Domcke, S., Sinha, R., Levine, D. A., Sander, C. & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013). · DOI · Paper page
  42. Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010). · DOI · Paper page
  43. Chen, B. et al. Relating chemical structure to cellular response: an integrative analysis of gene expression, bioactivity, and structural data across 11,000 compounds. CPT Pharmacometrics Syst. Pharmacol. 4, 576–584 (2015). · DOI
  44. Holliday, D. L. & Speirs, V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 13, 215 (2011). · DOI · Paper page
  45. Lacroix, M. & Leclercq, G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res. Treat. 83, 249–289 (2004). · DOI · Paper page
  46. Chen, Y., Li, Y., Narayan, R., Subramanian, A. & Xie, X. Gene expression inference with deep learning. Bioinformatics 32, 1832–1839 (2016). · DOI · Paper page
  47. Vidovic, D., Koleti, A. & Schurer, S. C. Large-scale integration of small molecule-induced genome-wide transcriptional responses, Kinome-wide binding affinities and cell-growth inhibition profiles reveal global trends characterizing systems-level drug action. Front. Genet. 5, 342 (2014).
  48. Cheng, J. et al. Evaluation of analytical methods for connectivity map data. Pac. Symp. Biocomput. 2013, 5–16, (2013).
  49. Duan, Q. et al. L1000CDS2: LINCS L1000 characteristic direction signatures search engine. NPJ Syst. Biol. Appl. 2, 16015 (2016). · DOI · Paper page
  50. van Westen, G. J., Gaulton, A. & Overington, J. P. Chemical, target, and bioactive properties of allosteric modulation. PLoS Comput. Biol. 10, e1003559 (2014). · DOI

Cited by

See all 215

Metadata

Authors
Chen, B., Ma, L., Paik, H., Sirota, M., Wei, W., Chua, M.-S., So, S., & Butte, A. J.
Venue
Nature Communications
Published
2017-07-12
Volume
8
Issue
1
Pages
16022-16022
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2734505834
Cited by
215
References
11
FWCI
11.97
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.